Skip to main content

European Consortium for Anticancer Antibody Development

Ziel

Cancer is the second leading cause of death in European countries, and one of the most imminent health problems in the developed world. Innovative, so-called targeted therapies are urgently needed that aim specifically at cancer cells or to cells of the stroma that support tumor growth. The ultimate goal of a targeted therapy is to increase anti-tumor efficacy with lowest possible side effects. Rapid and efficient translation of basic scientific advances into reagents, and targeted molecular leads for preclinical and clinical research and development based on scientific rationales and state-of-the-art technologies, optimally requires an interdisciplinary, collaborative, team-oriented approach. EUCAAD represents a virtual research institute in Europe and consists of 9 research participants including 4 SMEs devoted to the discovery and evaluation of new antibodies for therapy of human cancers. The consortium consists of researchers from SMEs and scientific and clinical centres that have gained international acclaim in this area of research, many of who have worked together in previous EU funded applications e.g. ANGIOSTOP, EUCAPS, ESTDAB and ENACT. Within the consortium there is unique expertise regarding target discovery, target validation, antibody production and initiation of clinical trials. As part of its efforts to translate laboratory research into viable cancer therapies the individual partners has accumulated an extensive portfolio of intellectual property providing a competitive edge to this application. The focus of the grant is the development and evaluation of antibodies against new target structures on tumour cells and blood vessels supplying tumours which are responsible for tumour angiogenesis, progression and metastasis. Collectively, the activities of this consortium can improve the cancer treatment standards in Europe and provide economic benefit to European biotechnology and pharmaceutical research by providing novel immunopharmaceuticals.

Wissenschaftliches Gebiet

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2007-A
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

CP-FP - Small or medium-scale focused research project

Koordinator

KAROLINSKA INSTITUTET
Adresse
Nobels Vag 5
17177 Stockholm
Schweden
Aktivitätstyp
Higher or Secondary Education Establishments
EU-Beitrag
€ 2 286 109,90
Kontakt Verwaltung
Maria Von Witting (Ms.)

Beteiligte (8)

BIOINVENT INTERNATIONAL AB
Schweden
EU-Beitrag
€ 1 068 920
Adresse
Soelvegatan 41
22370 Lund
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Stefan Ericsson (Mr.)
UNIVERSITE D'AIX MARSEILLE
Frankreich
EU-Beitrag
€ 532 098
Adresse
Boulevard Charles Livon 58
13284 Marseille
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Celine Damon (Ms.)
OXURION

Beteiligung beendet

Belgien
Adresse
Gaston Geenslaan 1
3001 Leuven
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Jean Marie Stassen (Dr.)
MARTIN-LUTHER-UNIVERSITAET HALLE-WITTENBERG
Deutschland
EU-Beitrag
€ 425 361
Adresse
Universitaetsplatz 10
6108 Halle (Saale)
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Peter Waehner (Dr.)
UNIVERSITA DEGLI STUDI DI TORINO
Italien
EU-Beitrag
€ 637 504
Adresse
Via Giuseppe Verdi 8
10124 Torino
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Eugenio Rinaldi (Dr.)
PHILOCHEM AG
Schweiz
EU-Beitrag
€ 309 206,80
Adresse
Libernstrasse 3
8112 Otelfingen
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Eveline Trachsel (Dr.)
PROTAGEN AG
Deutschland
EU-Beitrag
€ 456 640,70
Adresse
Otto-hahn-strasse 15
44227 Dortmund
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Sven Rüger (Mr.)
UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA
Italien
EU-Beitrag
€ 274 021,60
Adresse
Via Dei Vestini 31
66013 Chieti
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Luciana Gallo (Dr.)